Kate I Stevens, Eleni Frangou, Jae I L Shin, Hans-Joachim Anders, Annette Bruchfeld, Ulf Schönermarck, Thomas Hauser, Kerstin Westman, Gema M Fernandez-Juarez, Jürgen Floege, Dimitrios Goumenos, Kultigin Turkmen, Cees van Kooten, Stephen P McAdoo, Vladimir Tesar, Mårten Segelmark, Duvuru Geetha, David R W Jayne, Andreas Kronbichler
{"title":"Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS.","authors":"Kate I Stevens, Eleni Frangou, Jae I L Shin, Hans-Joachim Anders, Annette Bruchfeld, Ulf Schönermarck, Thomas Hauser, Kerstin Westman, Gema M Fernandez-Juarez, Jürgen Floege, Dimitrios Goumenos, Kultigin Turkmen, Cees van Kooten, Stephen P McAdoo, Vladimir Tesar, Mårten Segelmark, Duvuru Geetha, David R W Jayne, Andreas Kronbichler","doi":"10.1093/ndt/gfac052","DOIUrl":null,"url":null,"abstract":"<p><p>Patients with immune-mediated kidney diseases are at increased risk of severe coronavirus disease 2019 (COVID-19). The international rollout of COVID-19 vaccines has provided varying degrees of protection and enabled the understanding of vaccine efficacy and safety. The immune response to COVID-19 vaccines is lower in most patients with immune-mediated kidney diseases; either related to immunosuppression or comorbidities and complications caused by the underlying disease. Humoral vaccine response, measured by the presence of antibodies, is impaired or absent in patients receiving rituximab, mycophenolate mofetil (MMF), higher doses of glucocorticoids and likely other immunosuppressants, such as cyclophosphamide. The timing between the use of these agents and administration of vaccines is associated with the level of immune response: with rituximab, vaccine response can only be expected once B cells start to recover and patients with transient discontinuation of MMF mount a humoral response more frequently. The emergence of new COVID-19 variants and waning of vaccine-induced immunity highlight the value of a booster dose and the need to develop mutant-proof vaccines. COVID-19 vaccines are safe, exhibiting a very low risk of de novo or relapsing immune-mediated kidney disease. Population-based studies will determine whether this is causal or coincidental. Such cases respond to standard management, including the use of immunosuppression. The Immunonephrology Working Group and European Vasculitis Society recommend that patients with immune-mediated kidney diseases follow national guidance on vaccination. Booster doses based on antibody measurements could be considered.</p>","PeriodicalId":55492,"journal":{"name":"Aquatic Insects","volume":"15 1","pages":"1400-1410"},"PeriodicalIF":0.5000,"publicationDate":"2022-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9383521/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aquatic Insects","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ndt/gfac052","RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENTOMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Patients with immune-mediated kidney diseases are at increased risk of severe coronavirus disease 2019 (COVID-19). The international rollout of COVID-19 vaccines has provided varying degrees of protection and enabled the understanding of vaccine efficacy and safety. The immune response to COVID-19 vaccines is lower in most patients with immune-mediated kidney diseases; either related to immunosuppression or comorbidities and complications caused by the underlying disease. Humoral vaccine response, measured by the presence of antibodies, is impaired or absent in patients receiving rituximab, mycophenolate mofetil (MMF), higher doses of glucocorticoids and likely other immunosuppressants, such as cyclophosphamide. The timing between the use of these agents and administration of vaccines is associated with the level of immune response: with rituximab, vaccine response can only be expected once B cells start to recover and patients with transient discontinuation of MMF mount a humoral response more frequently. The emergence of new COVID-19 variants and waning of vaccine-induced immunity highlight the value of a booster dose and the need to develop mutant-proof vaccines. COVID-19 vaccines are safe, exhibiting a very low risk of de novo or relapsing immune-mediated kidney disease. Population-based studies will determine whether this is causal or coincidental. Such cases respond to standard management, including the use of immunosuppression. The Immunonephrology Working Group and European Vasculitis Society recommend that patients with immune-mediated kidney diseases follow national guidance on vaccination. Booster doses based on antibody measurements could be considered.
期刊介绍:
Aquatic Insects is an international journal publishing original research on the systematics, biology, and ecology of aquatic and semi-aquatic insects.
The subject of the research is aquatic and semi-aquatic insects, comprising taxa of four primary orders, the Ephemeroptera, Odonata, Plecoptera, and Trichoptera but also aquatic and semi-aquatic families of Hemiptera, Coleoptera, and Diptera, as well as specific representatives of Hymenoptera , Lepidoptera, Mecoptera, Megaloptera , and Neuroptera that occur in lotic and lentic habitats during part of their life cycle. Studies on other aquatic Hexapoda (i.e., Collembola) will be only accepted if space permits. Papers on other aquatic Arthropoda (e.g., Crustacea) will not be considered, except for those closely related to aquatic and semi-aquatic insects (e.g., water mites as insect parasites).
The topic of the research may include a wide range of biological fields. Taxonomic revisions and descriptions of individual species will be accepted especially if additional information is included on habitat preferences, species co-existing, behavior, phenology, collecting methods, etc., that are of general interest to an international readership. Descriptions based on single specimens are discouraged.
Detailed studies on morphology, physiology, behavior, and phenology of aquatic insects in all stadia of their life cycle are welcome as well as the papers with molecular and phylogenetic analyses, especially if they discuss evolutionary processes of the biological, ecological, and faunistic formation of the group.